ArticleThe Journal of clinical endocrinology and metabolism2026
Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
contextX-linked hypophosphatemia (XLH) is a rare disorder characterized by excess fibroblast growth factor 23 (FGF23), leading to chronic hypophosphatemia, osteomalacia, and rickets.
objectiveTo evaluate outcomes up to 3 years following initiation of treatment with anti-FGF23 antibody (burosumab) in a real-world setting among individuals with XLH, stratified by age group, including those excluded from clinical trials (<1, 13-17, and ≥65 years).
methodsThe XLH Disease Monitoring Program is a prospective, longitudinal, long-term-outcomes program for individuals with XLH. This analysis included participants who were burosumab-naive at baseline and who had initiated burosumab between baseline and the Year 1 visit. Changes from baseline in biochemistry, clinical outcomes, and patient-reported outcomes (PROs) were assessed at Year 1 (Y1) and Year 3 (Y3) visits.
resultsAmong participants (n = 139), burosumab led to significant and sustained improvements in mean (SD) serum phosphate z-scores at Y1 and Y3 (change from baseline: 1.4 [1.1]; P < .0001 for each timepoint). Among pediatric participants, serum alkaline phosphatase z-scores, Rickets Severity Scores, and patient-reported pain interference declined significantly at Y1 and Y3; non-significant changes were observed in fatigue and physical function mobility. Adults showed significant improvements in PRO measures of pain, stiffness, and physical function, with higher proportions of participants achieving minimal clinically important differences at Y3 vs Y1. Trends observed in overall cohorts were generally consistent across age sub-groups, with statistical significance reached for many endpoints.
conclusionThis analysis demonstrated the real-world effectiveness of burosumab for XLH, which appears evident across age groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.